Lipopolysaccharide binding protein, interleukin-6 and C-reactive protein in acute gastrointestinal infections: value as biomarkers to reduce unnecessary antibiotic therapy
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Several new biomarkers, such as lipopolysaccharide binding protein (LBP) and interleukin-6 (IL-6), have the potential to determine the severity and outcome of infectious diseases. LBP and IL-6 serum levels have not been reported in patients with gastrointestinal infections. The aim of this study was to compare established markers of infection with new markers, such as LBP and IL-6, in patients with acute gastrointestinal infections
LBP, C-reactive protein (CRP), white blood cell count (WBC) and IL-6 serum levels were determined in patients with acute viral or bacterial (positive stool cultures) gastroenteritis. The final diagnosis and empiric antibiotic use were recorded. In total, medical data on 88 patients with acute gastroenteritis (22 bacterial, 66 viral or nonspecific) were analyzed.
LBP and CRP levels were significantly increased in patients with acute bacterial gastroenteritis [28.5 ± 16.5 vs. 15.2 ± 11.5 μg/mL (p < 0.05) and 10.4 ± 9.6 vs. 3.8 ± 5.5 mg/dL (p < 0.001), respectively]. LBP at a cut-off value of 14.6 μg/mL and CRP at a cut-off value of 1.7 mg/dL distinguished between bacterial and non-bacterial gastrointestinal infection (receiver operator characteristic analysis). Empiric antibiotic therapy was initiated in 82% of patients with bacterial gastroenteritis and in 27% of patients with viral gastroenteritis.
The use of the cut-off values for LBP and CRP determined here would have avoided unnecessary antibiotic therapy in 14 and 11%, of patients respectively. CRP and LBP appear to be superior to IL-6 and WBC as diagnostic markers of bacterial gastrointestinal infection. Cut-off values may be a useful tool to support clinical decision-making on whether or not to initiate empiric antibiotic therapy.
- Pawlowski SW, Warren CA, Guerrant R. Diagnosis and treatment of acute or persistent diarrhea. Gastroenterology. 2009;136:1874–86. CrossRef
- Vernacchio L, Vezina RM, Mitchell AA, Lesko SM, Plaut AG, Acheson DW. Diarrhea in American infants and young children in the community setting: incidence, clinical presentation and microbiology. Pediatr Infect Dis J. 2006;25:2–7. CrossRef
- McCartney AC, Orange GV, Pringle SD, Wills G, Reece IJ. Serum C reactive protein in infective endocarditis. J Clin Pathol. 1988;41:44–8. CrossRef
- Gendrel D, Raymond J, Coste J, Moulin F, Lorrot M, Guérin S, Ravilly S, Lefèvre H, Royer C, Lacombe C, Palmer P, Bohuon C. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial versus viral infections. Pediatr Infect Dis J. 1999; 18: 875–81
- Schumann RR, Zweigner J. A novel acute-phase marker: lipopolysaccharide binding protein (LBP). Clin Chem Lab Med. 1999; 37:271–4
- Heumann D, Roger T. Initial responses to endotoxins and Gram-negative bacteria. Clin Chim Acta. 2002;323:59–72. CrossRef
- Palsson-McDermott EM, O’Neill LA. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 2004; 113:153–62
- Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer AJ, et al. Increased plasma levels of interleukin-6 in sepsis. Blood. 1989;74:1704–10.
- Wakefield CH, Barclay GR, Fearon KC, Goldie AS, Ross JA, Grant IS, et al. Proinflammatory mediator activity, endogenous antagonists and the systemic inflammatory response in intra-abdominal sepsis. Scottish Sepsis Intervention Group. Br J Surg. 1998; 85:818–25
- Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss–Dutch J5 Immunoglobulin Study Group. Am J Med. 1991; 91:23–9
- Le JM, Vilcek J. Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest. 1989;61:588–602.
- Lubasch A, Lode H. The role of antibiotic therapy in infectious enteritis. Internist. 2000;41:494–7. CrossRef
- Goossens H. Antibiotic consumption and link to resistance. Clin Microbiol Infect. 2009;15:12–5. CrossRef
- Blairon L, Wittebole X, Laterre PF. Lipopolysaccharide-binding protein serum levels in patients with severe sepsis due to Gram-positive and fungal infections. J Infect Dis. 2003; 187:287–91
- Pavcnik-Arnol M, Hojker S, Derganc M. Lipopolysaccharide-binding protein in critically ill neonates and children with suspected infection: comparison with procalcitonin, interleukin-6, and C-reactive protein. Intensive Care Med. 2004;30:1454–60. CrossRef
- Gaini S, Koldkjar OG, Pedersen C, Pedersen SS. Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. Crit Care 2006; 10:R53
- Gaini S, Koldkjar OG, Moller HJ, Pedersen C, Pedersen SS. A comparison of high-mobility group-box 1 protein, lipopolysaccharide-binding protein and procalcitonin in severe community-acquired infections and bacteraemia: a prospective study. Crit Care 2007; 11
- Sakr Y, Burgett U, Nacul FE, Reinhart K, Brunkhorst F. Lipopolysaccharide binding protein in a surgical intensive care unit: a marker of sepsis? Crit Care Med. 2008;36:2014–22. CrossRef
- Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999; 180:1584–9
- Masia M, Gutierrez F, Llorca B, Navarro JC, Mirete C, Padilla S, Hernandez I, Flores E. Serum concentrations of lipoplysaccharide-binding protein as a biochemical marker to differentiate microbial etiology in patients with community-acquired pneumonia. Clin Chem. 2004;50:1661–4. CrossRef
- Proulx F, Seidman E, Mariscalco MM, Lee K, Caroll S. Increased circulating levels of lipopolysaccharide binding protein in children with Escherichia coli O157:H7 hemorrhagic colitis and haemolytic uremic syndrome. Clin Diagn Lab Immunol. 1999; 6:773
- DuPont HL. Guidelines on acute infectious diarrhea in adults. The practice parameters committee of the American College of Gastroeneterology. Am J Gastroenetrol. 1997;92:1962–75.
- Dryden MS, Gabb RJ, Wright SK. Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin. Clin Infect Dis. 1996;22:1019–25. CrossRef
- Goodman LJ, Trenholme GM, Kaplan RL, Segreti J, Hines D, Petrak R, Nelson JA, Mayer KW, Landau W, Parkhurst GW, et al. Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. Arch Intern Med. 1990;150:541–6. CrossRef
- Cadwgan AM, Watson WA, Laing RB, MacKenzie AR, Smith CC, Douglas JG. Presenting clinical features and C-reactive protein in the prediction of a positive stool culture in patients with diarrhoea. J Infect. 2000;41:159–61. CrossRef
- Franz AR, Steinbach G, Kron M, Pohlandt F. Reduction of unnecessary antibiotic therapy in newborn infants using interleukin-8 and C-reactive protein as markers of bacterial infections. Pediatrics. 1999;104:447–53. CrossRef
- Gilbert DN. Use of plasma procalcitonin levels as an adjunct to clinical mirobiology. J Clin Microbiol. 2010;48:2325–9. CrossRef
- Lipopolysaccharide binding protein, interleukin-6 and C-reactive protein in acute gastrointestinal infections: value as biomarkers to reduce unnecessary antibiotic therapy
Volume 39, Issue 4 , pp 327-331
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Gastrointestinal infection
- Antibiotic therapy
- Industry Sectors
- Author Affiliations
- 1. Department of Gastroenterology and Medicine, St. Elisabeth Hospital, PO Box 580, 46225, Dorsten, Germany
- 2. Department of Gastroenterology, Infectious Diseases and Intoxications, University of Heidelberg, Heidelberg, Germany
- 3. Quality Center for Drug Safety and Diagnostics, Psychatric Services Aargau, Brugg, Switzerland